The trajectory of copyright's flagship drug presents a nuanced case for observers in the drug sector. While initially a phenomenal success, generating billions, the exclusivity end and the subsequent flood of off-brand alternatives have drastically affected revenue. This raises questions about the future profitability of related medication proje… Read More